Oncotelic Therapeutics Net Income
| OTLC Stock | USD 0.07 0.01 12.50% |
As of the 9th of February, Oncotelic Therapeutics holds the Risk Adjusted Performance of (0.04), variance of 53.9, and Coefficient Of Variation of (1,759). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncotelic Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Oncotelic Therapeutics, which can be compared to its competitors.
Oncotelic Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oncotelic Therapeutics' valuation are provided below:Oncotelic Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Oncotelic |
Oncotelic Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncotelic Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncotelic Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Oncotelic Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Oncotelic Therapeutics or generate 0.0% return on investment in Oncotelic Therapeutics over 90 days. Oncotelic Therapeutics is related to or competes with Relief Therapeutics, Relief Therapeutics, Arch Biopartners, Covalon Technologies, Helix BioPharma, Cannabix Technologies, and Zivo Bioscience. Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment ... More
Oncotelic Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncotelic Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncotelic Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 47.22 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 14.29 |
Oncotelic Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncotelic Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncotelic Therapeutics' standard deviation. In reality, there are many statistical measures that can use Oncotelic Therapeutics historical prices to predict the future Oncotelic Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.07) |
Oncotelic Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (1.06) | |||
| Mean Deviation | 4.09 | |||
| Coefficient Of Variation | (1,759) | |||
| Standard Deviation | 7.34 | |||
| Variance | 53.9 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.07) | |||
| Maximum Drawdown | 47.22 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 14.29 | |||
| Skewness | 0.3761 | |||
| Kurtosis | 2.63 |
Oncotelic Therapeutics Backtested Returns
Oncotelic Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.0212, which implies the firm had a -0.0212 % return per unit of risk over the last 3 months. Oncotelic Therapeutics exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oncotelic Therapeutics' Variance of 53.9, risk adjusted performance of (0.04), and Coefficient Of Variation of (1,759) to confirm the risk estimate we provide. The company holds a Beta of 0.4, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oncotelic Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncotelic Therapeutics is expected to be smaller as well. At this point, Oncotelic Therapeutics has a negative expected return of -0.15%. Please make sure to check Oncotelic Therapeutics' information ratio, as well as the relationship between the potential upside and day median price , to decide if Oncotelic Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Oncotelic Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Oncotelic Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncotelic Therapeutics price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Oncotelic Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oncotelic Therapeutics reported net income of (9.39 Million). This is 102.75% lower than that of the Healthcare sector and 113.41% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.64% higher than that of the company.
Oncotelic Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncotelic Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Oncotelic Therapeutics could also be used in its relative valuation, which is a method of valuing Oncotelic Therapeutics by comparing valuation metrics of similar companies.Oncotelic Therapeutics is currently under evaluation in net income category among its peers.
Oncotelic Fundamentals
| Return On Equity | 0.5 | |||
| Return On Asset | -0.13 | |||
| Current Valuation | 31.34 M | |||
| Shares Outstanding | 391.11 M | |||
| Shares Owned By Insiders | 55.93 % | |||
| Number Of Shares Shorted | 662.75 K | |||
| Price To Earning | 2.16 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 8.40 X | |||
| Gross Profit | 1.74 M | |||
| EBITDA | (8.45 M) | |||
| Net Income | (9.39 M) | |||
| Cash And Equivalents | 399.77 K | |||
| Total Debt | 9.8 M | |||
| Debt To Equity | 0.40 % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (4.43 M) | |||
| Short Ratio | 8.04 X | |||
| Earnings Per Share | 0.02 X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 16 | |||
| Beta | 0.19 | |||
| Market Capitalization | 23.9 M | |||
| Total Asset | 23.61 M | |||
| Z Score | 1.2 | |||
| Net Asset | 23.61 M |
About Oncotelic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncotelic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncotelic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncotelic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Oncotelic OTC Stock
Oncotelic Therapeutics financial ratios help investors to determine whether Oncotelic OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncotelic with respect to the benefits of owning Oncotelic Therapeutics security.